| Identification | Back Directory | [Name]
Salvianolicacid C | [CAS]
115841-09-3 | [Synonyms]
Salvianolicacid C
(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)- 7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoic acid
Benzenepropanoic acid, a-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-,(aR)-
Benzenepropanoic acid, α-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-, (αR)-
(alphaR)-alpha-[[(2E)-3-[2-(3,4-Dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxybenzenepropanoic acid | [Molecular Formula]
C26H20O10 | [MDL Number]
MFCD16660675 | [MOL File]
115841-09-3.mol | [Molecular Weight]
492.43 |
| Chemical Properties | Back Directory | [Boiling point ]
844.2±65.0 °C(Predicted) | [density ]
1.570 | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in methanol and water | [form ]
powder | [pka]
2.76±0.10(Predicted) | [color ]
Yellow | [InChIKey]
GCJWPRRNLSHTRY-QKKCHETFNA-N | [SMILES]
C(O)(=O)[C@H](OC(=O)/C=C/C1=C2C(=C(O)C=C1)OC(C1=CC=C(O)C(O)=C1)=C2)CC1=CC=C(O)C(O)=C1 |&1:3,r| |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Salvia miltiorrhiza. | [Uses]
Salvianoic Acid C is found in Danshen, a well-?known traditional Chinese medicine (TCM) used to treat cardiovascular and cerebrovascular diseases. | [Definition]
ChEBI: Salvianolic acid C is a member of benzofurans. | [in vivo]
Salvianolic acid C (20 mg/kg) treatment could significantly decrease the escape latency. In addition, SalC (10 and 20 mg/kg) treatment significantly increase the platform crossing number compared with the LPS model group. Systemic administration of Salvianolic acid C down regulates the brain TNF-α, IL-1β and IL-6 levels compared with the model group. The iNOS and COX-2 levels in rat brain cortex and hippocampus are higher than that in the control group, while Salvianolic acid C treatment significantly down regulates the cortex and hippocampus regions. Salvianolic acid C (5, 10 and 20 mg/kg) treatment dose-dependently increases the p-AMPK, Nrf2, HO-1 and NQO1 levels in rat brain cortex and hippocampus[2]. | [IC 50]
CYP2C8: 4.82 μM (Ki); CYP2J2: 5.75 μM (Ki) |
|
|